SGLT2 inhibitors : kidney as a new therapeutic target for type 2 diabetes

被引：0

作者：

Bons, Justine ^{[1
]}

Prevost, Gaetan ^{[2
,3
]}

机构：

[1] CHU Rouen, Serv Endocrinol Diabete & Malad Metab, Rouen, France

[2] INSERM, U982, F-76821 Mont St Aignan, France

[3] Univ Rouen, Inst Rech Innovat Biomed, F-76821 Mont St Aignan, France

来源：

CORRESPONDANCES EN METABOLISMES HORMONES DIABETES ET NUTRITION | 2015年 / 19卷 / 07期

关键词：

Kidney; Type; 2; diabetes; SGLT2; Gliflozine; COTRANSPORTER; 2; INHIBITORS; PROXIMAL TUBULAR CELLS; GLUCOSE TRANSPORTERS; RENAL GLUCOSURIA; SODIUM; REABSORPTION; HOMEOSTASIS; EXPRESSION; LIVER;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Kidney is a major player in glucose homeostasis that products 20 to 25% of glucose released in circulation and reabsorbs almost all glucose filtered by the glomerules. Glucose is mainly reabsorbed at proximal renal tubules apical membrane by sodium-glucose cotransporter SGLT2 through a Na/K/ATPase pump located at basal membrane. Glucose is then passively diffused in plasma at basal membrane by GLUT1 and GLUT2 transporters. Glucose renal reabsorption capacity is increased in type 2 diabetes, due to SGLT2 overexpression. Gliflozins are new antidiabetics agents able to inhibit SGLT2 and significantly increase glycosuria. They significantly decrease glycated hemoglobin, weight and systolic blood pressure. Their safety is still being evaluated.

引用

页码：191 / 195

页数：5

共 50 条

[1] The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors
Weir, Matthew R.
POSTGRADUATE MEDICINE, 2016, 128 (03) : 290 - 298
[2] SGLT2 Inhibitors for Type 2 Diabetes
Liu, Jiwen
Lee, TaeWeon
ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 46, 2011, 46 : 103 - +
[3] The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors
Cangoz, S.
Chang, Y. -Y.
Chempakaseril, S. J.
Guduru, R. C.
Huynh, L. M.
John, J. S.
John, S. T.
Joseph, M. E.
Judge, R.
Kimmey, R.
Kudratov, K.
Lee, P. J.
Madhani, I. C.
Shim, P. J.
Singh, S.
Singh, S.
Ruchalski, C.
Raffa, R. B.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2013, 38 (05) : 350 - 359
[4] SGLT2 Inhibitors: A New Emerging Therapeutic Class in the Treatment of Type 2 Diabetes Mellitus
Ghosh, Raktim Kumar
Ghosh, Samhati Mondal
Chawla, Shalini
Jasdanwala, Sarfaraz Abdeli
JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 52 (04): : 457 - 463
[5] SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus
Misra, Monika
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2013, 65 (03) : 317 - 327
[6] SGLT2 Inhibitors for the Prevention of Kidney Failure in Patients with Type 2 Diabetes
Pavlicek, Vojtech
DIABETOLOGE, 2019, 15 (07): : 663 - 664
[7] SGLT2 inhibitors in the treatment of type 2 diabetes
Hasan, Farhad M.
Alsahli, Mazen
Gerich, John E.
DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 104 (03) : 297 - 322
[8] SGLT2 inhibitors in the management of type 2 diabetes
R. P. Monica Reddy
Silvio E. Inzucchi
Endocrine, 2016, 53 : 364 - 372
[9] SGLT2 inhibitors in the management of type 2 diabetes
Reddy, R. P. Monica
Inzucchi, Silvio E.
ENDOCRINE, 2016, 53 (02) : 364 - 372
[10] SGLT2 Inhibitors in Type 2 Diabetes Mellitus
Ferrannini, Giulia
Savarese, Gianluigi
Cosentino, Francesco
HEART FAILURE CLINICS, 2022, 18 (04) : 551 - 559

← 1 2 3 4 5 →